Engineered extracellular vesicles antagonize SARS-CoV-2 infection by inhibiting mTOR signaling
Open Access
- 1 June 2022
- journal article
- Published by Elsevier BV in Biomaterials and Biosystems
- Vol. 6, 100042
- https://doi.org/10.1016/j.bbiosy.2022.100042
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportThe New England Journal of Medicine, 2020
- Augmenting canonical Wnt signalling in therapeutically inert cells converts them into therapeutically potent exosome factoriesNature Biomedical Engineering, 2019
- The advantages and limitations of mesenchymal stem cells in clinical application for treating human diseasesOsteoporosis and Sarcopenia, 2018
- Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replicationPLoS Pathogens, 2017
- Exosomes: Fundamental Biology and Roles in Cardiovascular PhysiologyAnnual Review of Physiology, 2016
- Exosomes in bodily fluids are a highly stable resource of disease biomarkersProteomics – Clinical Applications, 2015
- Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome AnalysisAntimicrobial Agents and Chemotherapy, 2015
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- IRES-Dependent Translational Control during Virus-Induced Endoplasmic Reticulum Stress and ApoptosisFrontiers in Microbiology, 2012
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genomeBMC Bioinformatics, 2011